{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:55:09Z","timestamp":1789505709202,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"vor","delay-in-days":41,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Heart Journal"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ihj.2024.06.002","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T17:40:44Z","timestamp":1718214044000},"page":"159-166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of the efficacy, safety, and tolerability of the FDC of telmisartan + bisoprolol with telmisartan + metoprolol succinate ER combination therapy for stage 1 and stage 2 hypertension: A double-blind, multicentric, phase-III clinical study"],"prefix":"10.1016","volume":"76","author":[{"given":"Gurpreet S","family":"Wander","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhim","family":"Ram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyendra","family":"Kumar Sonkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CN","family":"Manjunath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padmanabh","family":"Kamath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Sreenivasamurthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Balamurugan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SSVV","family":"Narasinga Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debabrata","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prajapati","family":"Vipulkumar Bachubhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjula","family":"S","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Kumar M","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ihj.2024.06.002_bib1","unstructured":"Hypertension [Internet]. [cited 2023 June 30]. Available from: https:\/\/www.who.int\/india\/health-topics\/hypertension."},{"issue":"11","key":"10.1016\/j.ihj.2024.06.002_bib2","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/s41371-020-0349-x","article-title":"Indian guidelines on hypertension-IV (2019)","volume":"34","author":"Shah","year":"2020","journal-title":"J Hum Hypertens"},{"issue":"3, Supplement","key":"10.1016\/j.ihj.2024.06.002_bib3","doi-asserted-by":"crossref","first-page":"S211","DOI":"10.1016\/S0002-8703(99)70312-1","article-title":"Elevated systolic blood pressure and risk of cardiovascular and renal disease: Overview of evidence from observational epidemiologic studies and randomized controlled trials","volume":"138","author":"He","year":"1999","journal-title":"Am Heart J"},{"issue":"4","key":"10.1016\/j.ihj.2024.06.002_bib4","first-page":"229","article-title":"Prevention of cardiovascular diseases: role of exercise, dietary interventions, obesity and smoking cessation","volume":"10","author":"Buttar","year":"2005","journal-title":"Exp Clin Cardiol"},{"issue":"19","key":"10.1016\/j.ihj.2024.06.002_bib5","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure the JNC 7 Report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ihj.2024.06.002_bib6","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40119-019-0144-3","article-title":"New American and European hypertension guidelines, reconciling the differences","volume":"8","author":"de la Sierra","year":"2019","journal-title":"Cardiol Ther"},{"issue":"28","key":"10.1016\/j.ihj.2024.06.002_bib7","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","article-title":"2013 ESH\/ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"34","author":"Mancia","year":"2013","journal-title":"Eur Heart J"},{"issue":"7160","key":"10.1016\/j.ihj.2024.06.002_bib8","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38","volume":"317","year":"1998","journal-title":"BMJ"},{"issue":"9127","key":"10.1016\/j.ihj.2024.06.002_bib9","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(05)79282-5","article-title":"Hypertension optimal treatment (HOT) trial","volume":"352","author":"Cruickshank","year":"1998","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ihj.2024.06.002_bib10","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s00508-018-1435-8","article-title":"What's new in the ESC 2018 guidelines for arterial hypertension. The ten most important messages","volume":"131","author":"Bergler-Klein","year":"2019","journal-title":"Wien Klin Wochenschr"},{"issue":"22","key":"10.1016\/j.ihj.2024.06.002_bib11","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ihj.2024.06.002_bib12","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.cjca.2016.02.066","article-title":"Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension","volume":"32","author":"Leung","year":"2016","journal-title":"Can J Cardiol"},{"issue":"19","key":"10.1016\/j.ihj.2024.06.002_bib13","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"Whelton","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"33","key":"10.1016\/j.ihj.2024.06.002_bib14","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension: the task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"issue":"23","key":"10.1016\/j.ihj.2024.06.002_bib15","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients","volume":"359","author":"Jamerson","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2024.06.002_bib16","unstructured":"PubChem. Bisoprolol [Internet]. [cited 2023 June 30]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/2405."},{"key":"10.1016\/j.ihj.2024.06.002_bib17","unstructured":"PubChem. Telmisartan [Internet]. [cited 2023 June 30]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/65999."},{"issue":"Suppl 3","key":"10.1016\/j.ihj.2024.06.002_bib18","first-page":"A245","article-title":"213 Consensus towards the utilisation of bisoprolol in combination with telmisartan in Indian patients with hypertension","volume":"109","author":"Sawhney","year":"2023","journal-title":"Heart"},{"issue":"5","key":"10.1016\/j.ihj.2024.06.002_bib19","doi-asserted-by":"crossref","first-page":"367","DOI":"10.18203\/2349-3933.ijam20231071","article-title":"Management of hypertensive patients with ischemic heart disease and the role of a fixed-dose combination of telmisartan and metoprolol: a physician-based research survey","volume":"10","author":"Kathiresan","year":"2023","journal-title":"Int J Adv Medicine"},{"key":"10.1016\/j.ihj.2024.06.002_bib20","first-page":"124","article-title":"Comparative study of fixed dose combination of olmesartan +amlodipine vs telmesartan+metoprolol in stage I and stage II hypertensive patients and also check their effects on lipid metabolism","author":"Shah","year":"2013","journal-title":"Asian J Pharmaceut Clin Res"},{"issue":"4","key":"10.1016\/j.ihj.2024.06.002_bib21","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ihj.2014.05.020","article-title":"To compare the effect of Telmisartan with Metoprolol on arterial stiffness in hypertension: prospective randomized parallel group trial","volume":"66","author":"Sumbria","year":"2014","journal-title":"Indian Heart J"},{"issue":"3","key":"10.1016\/j.ihj.2024.06.002_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2011-000683","article-title":"Efficacy and tolerability of a \u03b2-1 selective \u03b2 blocker, bisoprolol, as a first-line antihypertensive in Indian patients diagnosed with essential hypertension (BRIGHT): an open-label, multicentric observational study","volume":"2","author":"Channaraya","year":"2012","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.ihj.2024.06.002_bib23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40119-015-0045-z","article-title":"Treatment of hypertensive patients with a fixed-dose combination of bisoprolol and amlodipine: results of a cohort study with more than 10,000 patients","volume":"4","author":"Hostalek","year":"2015","journal-title":"Cardiol Ther"},{"issue":"4","key":"10.1016\/j.ihj.2024.06.002_bib24","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s10557-021-07248-1","article-title":"The combination of beta-blockers and ACE inhibitors across the spectrum of cardiovascular diseases","volume":"37","author":"Strauss","year":"2023","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"10.1016\/j.ihj.2024.06.002_bib25","article-title":"Efficacy and safety of bisoprolol compared to other selective beta-1 blockers in the treatment of hypertension: a systematic review and meta-analysis of randomized parallel clinical trials","volume":"42","author":"Jadhav","year":"2021","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.ihj.2024.06.002_bib26","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/00926239208412857","article-title":"Bisoprolol and hypertension: effects on sexual functioning in men","volume":"18","author":"Broekman","year":"1992","journal-title":"J Sex Marital Ther"},{"issue":"12","key":"10.1016\/j.ihj.2024.06.002_bib27","first-page":"33","article-title":"The analysis of adhesive-dysfunctional endothely at resistant arterial hypertension","volume":"4","author":"Mouna","year":"2017","journal-title":"Science: Med Sci"},{"issue":"4","key":"10.1016\/j.ihj.2024.06.002_bib28","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s40256-016-0165-4","article-title":"The different therapeutic choices with ARBs. Which one to give? When? Why?","volume":"16","author":"D\u00e9zsi","year":"2016","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.ihj.2024.06.002_bib29","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1097\/CM9.0000000000000802","article-title":"Resting heart rate control and prognosis in coronary artery disease patients with hypertension previously treated with bisoprolol: a sub-group analysis of the BISO-CAD study","volume":"133","author":"Chen","year":"2020","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.ihj.2024.06.002_bib30","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/s41371-020-0349-x","article-title":"Indian guidelines on hypertension-IV (2019)","volume":"34","author":"Shah","year":"2020","journal-title":"J Hum Hypertens"}],"container-title":["Indian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019483224000750?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019483224000750?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T12:38:59Z","timestamp":1722256739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0019483224000750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0019483224000750"],"URL":"https:\/\/doi.org\/10.1016\/j.ihj.2024.06.002","relation":{},"ISSN":["0019-4832"],"issn-type":[{"value":"0019-4832","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of the efficacy, safety, and tolerability of the FDC of telmisartan + bisoprolol with telmisartan + metoprolol succinate ER combination therapy for stage 1 and stage 2 hypertension: A double-blind, multicentric, phase-III clinical study","name":"articletitle","label":"Article Title"},{"value":"Indian Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ihj.2024.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Cardiological Society of India. Published by Elsevier, a division of RELX India, Pvt. Ltd.","name":"copyright","label":"Copyright"}]}}